Pharmaceutical shipments between Europe and Brazil have jumped 150% at LATAM Cargo in the first seven months of the year, with GLP-1-based medications doing most of the pulling.

The figure compares with the same period in 2025. It lands alongside a broader surge on the lane: the carrier moved nearly 32,000 tonnes of cargo between Europe and Brazil over those seven months, up 27% year on year.

That is the standout number in an air cargo market the carrier describes as otherwise flat globally. One trade lane is running hot. The rest of the board barely moves.

What's driving the spike?

The engine is GLP-1 medicines — the drug class used in treatments for type 2 diabetes and best known commercially through brands such as Ozempic and Wegovy, though the source does not name specific products. Production of these treatments is concentrated in Europe, largely Denmark, while demand is scaling fast across emerging markets, Brazil among them.

That geography explains the lane. Cold-chain-capable capacity out of Europe into South America is limited, and pharma freight pays a premium for it. A 150% rise in pharma tonnage is not marginal growth absorbed by existing belly space; it is the kind of shift that reshapes how a carrier allocates widebody capacity and freighter rotations on a route.

What does this change for shippers and forwarders?

For pharma shippers, the practical question is capacity security. A lane growing this quickly tends to tighten: rates on temperature-controlled allocations rise first, and forwarders with contracted cool-chain space on Europe–Brazil will hold an advantage over spot buyers. Shippers moving standard freight on the same lane should watch for capacity crowding-out, because pharma's premium rates push general cargo toward remaining belly hold.

For LATAM Cargo, the growth validates a lane strategy built around Brazil's deepening pharmaceutical demand. A 27% rise in total tonnage — pharma plus everything else — shows the lane's strength isn't confined to one commodity, even if GLP-1s supplied the acceleration.

For competitors, the signal is harder to ignore. Lufthansa Cargo, IAG Cargo and others serve Europe–South America, and a 150% pharma surge on one carrier's books suggests traffic others will want a share of.

The flat market backdrop

The contrast is the story. LATAM Cargo reports the global air cargo market as flat, which makes a 150% lane-level gain look less like a market trend and more like a structural demand shift — one commodity class, one origin region, one destination market, growing fast against a static baseline.

Flat global conditions also limit the supply response. Carriers aren't adding widebody capacity broadly in a flat market, so the freighter and belly space available to serve Europe–Brazil growth comes largely from redeployment, not new metal. That supports rates on the lane even as global pricing softens.

The trajectory from here depends on GLP-1 production volumes, which keep expanding as manufacturers scale plants, and on whether Brazil's uptake curve continues. Seven months of data point one direction; the pace will decide how much capacity LATAM Cargo and its rivals commit to the lane next.